## **G**uy Rostoker

## List of Publications by Citations

Source: https://exaly.com/author-pdf/4494334/guy-rostoker-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50
papers

1,236
citations

18
papers
h-index

34
g-index

4.25
ext. papers

ext. citations

18
papers
avg, IF

L-index

#	Paper	IF	Citations
50	COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, 1973-1983	4.3	134
49	Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. <i>American Journal of Medicine</i> , <b>2012</b> , 125, 991-999.e1	2.4	118
48	High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schilein purpura. <i>Annals of Internal Medicine</i> , <b>1994</b> , 120, 476-84	8	85
47	Schilein-henoch purpura in children and adults: diagnosis, pathophysiology and management. <i>BioDrugs</i> , <b>2001</b> , 15, 99-138	7.9	69
46	A modified Cockcroft-Gault formula taking into account the body surface area gives a more accurate estimation of the glomerular filtration rate. <i>Journal of Nephrology</i> , <b>2007</b> , 20, 576-85	4.8	46
45	latrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century. <i>Drugs</i> , <b>2016</b> , 76, 741-	· <b>57</b> 2.1	44
44	Immunomodulation with low-dose immunoglobulins for moderate IgA nephropathy and Henoch-Schilein purpura. Preliminary results of a prospective uncontrolled trial. <i>Nephron</i> , <b>1995</b> , 69, 327-34	3.3	41
43	Vascular hyperpermeability in nephrotic edema. <i>Nephron</i> , <b>2000</b> , 85, 194-200	3.3	40
42	Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. <i>Nephron</i> , <b>1993</b> , 63, 335-41	3.3	40
41	An increase in circulating IgA antibodies to gliadin in IgA mesangial glomerulonephritis. <i>American Journal of Nephrology</i> , <b>1987</b> , 7, 178-83	4.6	35
40	Renal artery stenosis evaluation in chronic kidney disease patients: nonenhanced time-spatial labeling inversion-pulse three-dimensional MR angiography with regulated breathing versus DSA. <i>Radiology</i> , <b>2011</b> , 259, 592-601	20.5	33
39	Renal involvement in toxic epidermal necrolysis. <i>Journal of the American Academy of Dermatology</i> , <b>1996</b> , 34, 1088-90	4.5	32
38	Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0132006	3.7	29
37	Increased intestinal intra-epithelial T lymphocytes in primary glomerulonephritis: a role of oral tolerance breakdown in the pathophysiology of human primary glomerulonephritides?. <i>Nephrology Dialysis Transplantation</i> , <b>2001</b> , 16, 513-7	4.3	27
36	Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. <i>Nephron</i> , <b>1995</b> , 69, 20-8	3.3	27
35	Role of lipoprotein-bound NEFAs in enhancing the specific activity of plasma CETP in the nephrotic syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology,</i> <b>1997</b> , 17, 2559-67	9.4	23
34	latrogenic iron overload and its potential consequences in patients on hemodialysis. <i>Presse Medicale</i> , <b>2017</b> , 46, e312-e328	2.2	18

33	Maximal standard dose of parenteral iron for hemodialysis patients: an MRI-based decision tree learning analysis. <i>PLoS ONE</i> , <b>2014</b> , 9, e115096	3.7	17	
32	Liver Iron Load Influences Hepatic Fat Fraction in End-Stage Renal Disease Patients on Dialysis: A Proof of Concept Study. <i>EBioMedicine</i> , <b>2019</b> , 39, 461-471	8.8	15	
31	Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations. <i>Heliyon</i> , <b>2019</b> , 5, e02045	3.6	13	
30	Candesartan cilexetil on regular hemodialysis: inability to reduce excessive thirst, but good tolerance and efficacy in hypertensive patients. <i>Renal Failure</i> , <b>2006</b> , 28, 283-6	2.9	12	
29	A pilot study of routine colloid infusion in hypotension-prone dialysis patients unresponsive to preventive measures. <i>Journal of Nephrology</i> , <b>2011</b> , 24, 208-17	4.8	12	
28	Improving the efficiency of short-term single-needle hemodialysis. <i>Renal Failure</i> , <b>2009</b> , 31, 261-6	2.9	11	
27	Low prevalence of antibodies to hepatitis C virus among adult patients with idiopathic membranoproliferative type I glomerulonephritis in France. <i>Nephron</i> , <b>1995</b> , 69, 97	3.3	11	
26	Signal-intensity-ratio MRI accurately estimates hepatic iron load in hemodialysis patients. <i>Heliyon</i> , <b>2017</b> , 3, e00226	3.6	10	
25	Left-ventricular diastolic dysfunction as a risk factor for dialytic hypotension. <i>Cardiology</i> , <b>2009</b> , 114, 14	1 <b>2-9</b> .6	8	
24	Parvovirus B19 and Schilein-Henoch purpura in adults. <i>Nephron</i> , <b>1999</b> , 83, 172	3.3	8	
23	Magnetic resonance imaging repercussions of intravenous iron products used for iron-deficiency anemia and dialysis-associated anemia. <i>Journal of Computer Assisted Tomography</i> , <b>2014</b> , 38, 843-4	2.2	7	
22	Hepatic Iron Load at Magnetic Resonance Imaging Is Normal in Most Patients Receiving Peritoneal Dialysis. <i>Kidney International Reports</i> , <b>2017</b> , 2, 1219-1222	4.1	7	
21	Accuracy and limitations of equations for predicting the glomerular filtration rate during follow-up of patients with non-diabetic nephropathies. <i>BMC Nephrology</i> , <b>2009</b> , 10, 16	2.7	7	
20	Further identification of human plasma glycoproteins interacting with the galactose-specific lectin Jacalin. <i>Biomedical Applications</i> , <b>1995</b> , 668, 1-11		7	
19	Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution. <i>Hemodialysis International</i> , <b>2017</b> , 21 Suppl 1, S68-S77	1.7	6	
18	Modulation of oxidative stress and microinflammatory status by colloids in refractory dialytic hypotension. <i>BMC Nephrology</i> , <b>2011</b> , 12, 58	2.7	6	
17	Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study. <i>BMC Nephrology</i> , <b>2017</b> , 18, 97	2.7	5	
16	Histological Scores Validate the Accuracy of Hepatic Iron Load Measured by Signal Intensity Ratio and R2* Relaxometry MRI in Dialysis Patients. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 9,	5.1	5	

15	Therapy of IgA nephropathy. <i>BioDrugs</i> , <b>1998</b> , 9, 279-301	7.9	4
14	Evaluation of magnetic resonance imaging for the assessment of renal vein thrombosis in the nephrotic syndrome. <i>Nephron</i> , <b>1994</b> , 68, 271-2	3.3	4
13	Coexistence of SDary syndrome and dysmyelopoiesis with an excess of myeloblasts. <i>Journal of the American Academy of Dermatology</i> , <b>1986</b> , 15, 1296-8	4.5	4
12	Cinacalcet to prevent parathyrotoxic crises in hypercalcaemic patients awaiting parathyroidectomy. <i>BMJ Case Reports</i> , <b>2011</b> , 2011,	0.9	4
11	A cost analysis of the prevention of end-stage renal disease: immunoglobulin therapy for IgA nephropathy. <i>Medical Decision Making</i> , <b>1996</b> , 16, 326-34	2.5	3
10	What do we learn about the Anemia Module of the French language Peritoneal Dialysis? Interest and Results. <i>Bulletin De La Dialyse</i> Domicile, <b>2019</b> , 2, 143-149	1	2
9	Analysis of Other Confounding Factors Is Mandatory before Considering That Long-Acting Erythropoiesis Stimulating Agents Are Deleterious to Patients on Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2019</b> , 30, 1771	12.7	2
8	HFE gene mutations are not risk factors for iron overload in European hemodialysis patients. <i>Hemodialysis International</i> , <b>2017</b> , 21, 440-442	1.7	1
7	Re: Further Evidence Supporting the Accuracy of Quantitative Magnetic Resonance Imaging for Evaluating Iron Load in Dialysis Patients. <i>Kidney International Reports</i> , <b>2018</b> , 3, 217-218	4.1	1
6	Heparin cofactor II in adult glomerulopathy and nephrotic syndrome. <i>American Journal of Nephrology</i> , <b>1991</b> , 11, 74-5	4.6	1
5	Use of Iron Therapy in Chronic Kidney Disease. Archives of Clinical Nephrology,001-003	O	1
4	Why and how should we promote home dialysis for patients with end-stage kidney disease during and after the coronavirus 2019 disease pandemic? A French perspective. <i>Journal of Nephrology</i> , <b>2021</b> , 34, 985-989	4.8	1
3	Analysis of liver iron concentration in an elderly female undergoing hemodialysis with calcific uremic arteriolopathy does not support the role of iron overload in calciphylaxis: lesson for the clinical nephrologist. <i>Journal of Nephrology</i> , <b>2021</b> , 34, 1547-1551	4.8	1

Therapy of Idiopathic Membranous Nephropathy. *BioDrugs*, **1996**, 6, 7-27